This review outlines a systematic evaluation for drug-induced lung disease in oncologic patients, highlighting pulmonary toxicity associated with therapies.
Key Points
Drug-induced interstitial lung disease is a notable complication of cancer therapies, increasing morbidity and mortality.
The National Cancer Institute estimates over 2 million cancer diagnoses in 2025, necessitating attention to treatment-related pulmonary issues.
A structured assessment approach for patients with malignancy presenting diffuse lung disease may improve management of suspected D-ILD.
Understanding the pulmonary toxicities of common cancer therapies is crucial for pulmonologists and oncologists to adapt treatment strategies.